Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Assets (2016 - 2025)

Catalyst Pharmaceuticals' Assets history spans 16 years, with the latest figure at $1.1 billion for Q4 2025.

  • For Q4 2025, Assets rose 29.66% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, up 29.66%, while the annual FY2025 figure was $1.1 billion, 29.66% up from the prior year.
  • Assets reached $1.1 billion in Q4 2025 per CPRX's latest filing, up from $1.1 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.1 billion in Q4 2025 to a low of $197.2 million in Q1 2021.
  • Average Assets over 5 years is $541.9 million, with a median of $428.6 million recorded in 2023.
  • Peak YoY movement for Assets: increased 23.62% in 2021, then skyrocketed 86.83% in 2024.
  • A 5-year view of Assets shows it stood at $237.8 million in 2021, then skyrocketed by 57.97% to $375.6 million in 2022, then rose by 25.15% to $470.1 million in 2023, then surged by 81.11% to $851.4 million in 2024, then rose by 29.66% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Assets are $1.1 billion (Q4 2025), $1.1 billion (Q3 2025), and $971.9 million (Q2 2025).